- 10:28 AM Financial stability, climate change top on EU Prez...
- 10:27 AM UK joins G20 push for world levy on banks
- 10:27 AM Britain urges divided G20 to reach climate finance...
- 10:27 AM G20 leaders meet, talk about climate change, world...
- 06:47 PM 'The Sensex will test 14,500 at some point…'
- 04:16 PM See scope for more int'l listings of Indian cos: N...
- 04:12 PM Dollar weakness will boost EMs, commodities ahead:...
- 04:07 PM 'India would've grown at 7% had monsoon not played...
- 03:04 PM Bye-bye Circular 23!
- 03:00 PM CavinKare eyes Rs 100cr revenues from restaurant b...
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for the company’s Abbreviated New Drug Application (ANDA) for generic Sinemet CR, an extended release version of carbidopa with levodopa.
Carbidopa with levodopa extended release is indicated for the treatment of Parkinson’s disease and syndrome.
These generic extended release versions of carbidopa with levodopa are bio-equivalent to Sinemet CR® marketed by Bristol-Myers and Squibb Company and will be available as tablets in two strengths: 25 mg carbidopa with 100 mg levodopa and 50 mg carbidopa with 200 mg levodopa.
These strengths of carbidopa with levodopa generic and branded products had annual sales of approximately USD 66 million in the US.
The Company expects to reach the market shortly with these products.
Sourced From: Sun Pharmaceutical Industries Ltd
|
|
Today's Special Column
with Kishore Biyani
Future Group and the MD of Pantaloon Retail (India) Limited , Group CEO
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 'The Sensex will test 14,500 at some point…'
- Mahindra Satyam restarts hirings, recalls bench
- Exit Suzlon Energy at Rs 83: Joshi
- 'Bullish' Mark Mobius unfazed by recent market correction
- Sensex ends week 262 pts up, sectors to look at ahead
- SBI cuts deposit rates on slow credit, liquidity glut
- 'The Sensex will test 14,500 at some point…'
Source: CNBC-TV18
- See scope for more int'l listings of Indian cos: NYSE
Source: CNBC-TV18
- Dollar weakness will boost EMs, commodities ahead: HSBC
Source: CNBC-TV18
- 'India would've grown at 7% had monsoon not played truant'
Source: CNBC-TV18
- SBI cuts deposit rates on slow credit, liquidity glut
Source: Business Line
- Aurobindo drug gets US nod
Source: Business Line
- BEML bags Rs 185 cr NCL order
Source: Business Line
- Tatas going global with low-cost housing
Source: Business Line
